Selected research
Market Structure
Global Etoricoxib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Etoricoxib market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Etoricoxib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Etoricoxib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Etoricoxib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Etoricoxib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Etoricoxib include Shanghai Shyndec Pharmaceutical, Qilu Pharmaceutical, Merck & Co, Easton Biopharmaceuticals, Beijing Tide Pharmaceutical, Morepen Laboratories, Metrochem API, Hema Pharmaceuticals and Frosst Iberica SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Etoricoxib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Etoricoxib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Etoricoxib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Etoricoxib market size, projected growth trends, production technologies, key applications, and end-use industries.
Etoricoxib Segment by Company
Shanghai Shyndec Pharmaceutical
Qilu Pharmaceutical
Merck & Co
Easton Biopharmaceuticals
Beijing Tide Pharmaceutical
Morepen Laboratories
Metrochem API
Hema Pharmaceuticals
Frosst Iberica SA
Atom Pharma
Etoricoxib Segment by Type
120 mg
30 mg
60 mg
90 mg
Etoricoxib Segment by Application
Hospital
Pharmacy
Others
Etoricoxib Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Etoricoxib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Etoricoxib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Etoricoxib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Etoricoxib market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Etoricoxib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Etoricoxib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Etoricoxib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 120 mg
- 30 mg
- 60 mg
- 90 mg
Applications
- Hospital
- Pharmacy
- Others
Companies covered
- Shanghai Shyndec Pharmaceutical
- Qilu Pharmaceutical
- Merck & Co
- Easton Biopharmaceuticals
- Beijing Tide Pharmaceutical
- Morepen Laboratories
- Metrochem API
- Hema Pharmaceuticals
- Frosst Iberica SA
- Atom Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Etoricoxib Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Etoricoxib Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Etoricoxib Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Etoricoxib Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Etoricoxib Market Dynamics
- 2.1 Etoricoxib Industry Trends
- 2.2 Etoricoxib Industry Drivers
- 2.3 Etoricoxib Industry Opportunities and Challenges
- 2.4 Etoricoxib Industry Restraints
3 Etoricoxib Market by Manufacturers
- 3.1 Global Etoricoxib Revenue by Manufacturers (2021-2026)
- 3.2 Global Etoricoxib Sales by Manufacturers (2021-2026)
- 3.3 Global Etoricoxib Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Etoricoxib Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Etoricoxib Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Etoricoxib Manufacturers, Product Type & Application
- 3.7 Global Etoricoxib Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Etoricoxib Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Etoricoxib Players Market Share by Revenue in 2025
- 3.8.3 2025 Etoricoxib Tier 1, Tier 2, and Tier 3
4 Etoricoxib Market by Type
- 4.1 Etoricoxib Type Introduction
- 4.1.1 120 mg
- 4.1.2 30 mg
- 4.1.3 60 mg
- 4.1.4 90 mg
- 4.2 Global Etoricoxib Sales by Type
- 4.2.1 Global Etoricoxib Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Etoricoxib Sales by Type (2021-2032)
- 4.2.3 Global Etoricoxib Sales Market Share by Type (2021-2032)
- 4.3 Global Etoricoxib Revenue by Type
- 4.3.1 Global Etoricoxib Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Etoricoxib Revenue by Type (2021-2032)
- 4.3.3 Global Etoricoxib Revenue Market Share by Type (2021-2032)
5 Etoricoxib Market by Application
- 5.1 Etoricoxib Application Introduction
- 5.1.1 Hospital
- 5.1.2 Pharmacy
- 5.1.3 Others
- 5.2 Global Etoricoxib Sales by Application
- 5.2.1 Global Etoricoxib Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Etoricoxib Sales by Application (2021-2032)
- 5.2.3 Global Etoricoxib Sales Market Share by Application (2021-2032)
- 5.3 Global Etoricoxib Revenue by Application
- 5.3.1 Global Etoricoxib Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Etoricoxib Revenue by Application (2021-2032)
- 5.3.3 Global Etoricoxib Revenue Market Share by Application (2021-2032)
6 Global Etoricoxib Sales by Region
- 6.1 Global Etoricoxib Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Etoricoxib Sales by Region (2021-2032)
- 6.2.1 Global Etoricoxib Sales by Region (2021-2026)
- 6.2.2 Global Etoricoxib Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Etoricoxib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Etoricoxib Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Etoricoxib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Etoricoxib Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Etoricoxib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Etoricoxib Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Etoricoxib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Etoricoxib Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Etoricoxib Revenue by Region
- 7.1 Global Etoricoxib Revenue by Region
- 7.1.1 Global Etoricoxib Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Etoricoxib Revenue by Region (2021-2026)
- 7.1.3 Global Etoricoxib Revenue by Region (2027-2032)
- 7.1.4 Global Etoricoxib Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Etoricoxib Revenue (2021-2032)
- 7.2.2 North America Etoricoxib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Etoricoxib Revenue (2021-2032)
- 7.3.2 Europe Etoricoxib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Etoricoxib Revenue (2021-2032)
- 7.4.2 Asia-Pacific Etoricoxib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Etoricoxib Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Etoricoxib Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Shanghai Shyndec Pharmaceutical
- 8.1.1 Shanghai Shyndec Pharmaceutical Company Information
- 8.1.2 Shanghai Shyndec Pharmaceutical Business Overview
- 8.1.3 Shanghai Shyndec Pharmaceutical Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Shanghai Shyndec Pharmaceutical Etoricoxib Product Portfolio
- 8.1.5 Shanghai Shyndec Pharmaceutical Recent Developments
- 8.2 Qilu Pharmaceutical
- 8.2.1 Qilu Pharmaceutical Company Information
- 8.2.2 Qilu Pharmaceutical Business Overview
- 8.2.3 Qilu Pharmaceutical Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Qilu Pharmaceutical Etoricoxib Product Portfolio
- 8.2.5 Qilu Pharmaceutical Recent Developments
- 8.3 Merck & Co
- 8.3.1 Merck & Co Company Information
- 8.3.2 Merck & Co Business Overview
- 8.3.3 Merck & Co Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck & Co Etoricoxib Product Portfolio
- 8.3.5 Merck & Co Recent Developments
- 8.4 Easton Biopharmaceuticals
- 8.4.1 Easton Biopharmaceuticals Company Information
- 8.4.2 Easton Biopharmaceuticals Business Overview
- 8.4.3 Easton Biopharmaceuticals Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Easton Biopharmaceuticals Etoricoxib Product Portfolio
- 8.4.5 Easton Biopharmaceuticals Recent Developments
- 8.5 Beijing Tide Pharmaceutical
- 8.5.1 Beijing Tide Pharmaceutical Company Information
- 8.5.2 Beijing Tide Pharmaceutical Business Overview
- 8.5.3 Beijing Tide Pharmaceutical Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Beijing Tide Pharmaceutical Etoricoxib Product Portfolio
- 8.5.5 Beijing Tide Pharmaceutical Recent Developments
- 8.6 Morepen Laboratories
- 8.6.1 Morepen Laboratories Company Information
- 8.6.2 Morepen Laboratories Business Overview
- 8.6.3 Morepen Laboratories Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Morepen Laboratories Etoricoxib Product Portfolio
- 8.6.5 Morepen Laboratories Recent Developments
- 8.7 Metrochem API
- 8.7.1 Metrochem API Company Information
- 8.7.2 Metrochem API Business Overview
- 8.7.3 Metrochem API Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Metrochem API Etoricoxib Product Portfolio
- 8.7.5 Metrochem API Recent Developments
- 8.8 Hema Pharmaceuticals
- 8.8.1 Hema Pharmaceuticals Company Information
- 8.8.2 Hema Pharmaceuticals Business Overview
- 8.8.3 Hema Pharmaceuticals Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Hema Pharmaceuticals Etoricoxib Product Portfolio
- 8.8.5 Hema Pharmaceuticals Recent Developments
- 8.9 Frosst Iberica SA
- 8.9.1 Frosst Iberica SA Company Information
- 8.9.2 Frosst Iberica SA Business Overview
- 8.9.3 Frosst Iberica SA Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Frosst Iberica SA Etoricoxib Product Portfolio
- 8.9.5 Frosst Iberica SA Recent Developments
- 8.10 Atom Pharma
- 8.10.1 Atom Pharma Company Information
- 8.10.2 Atom Pharma Business Overview
- 8.10.3 Atom Pharma Etoricoxib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Atom Pharma Etoricoxib Product Portfolio
- 8.10.5 Atom Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Etoricoxib Value Chain Analysis
- 9.1.1 Etoricoxib Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Etoricoxib Production Mode & Process
- 9.2 Etoricoxib Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Etoricoxib Distributors
- 9.2.3 Etoricoxib Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst